STK17B

Across TCGA pan-cancer cohorts, STK17B Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated STK17B data layer compared with 27 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher STK17B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated STK17B expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

ESCA, SARC, and PRAD are the cancer types where STK17B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.117	0.703	<.001	36	view →
SARC	OS	Median	All	0.108	0.839	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUSC	DFS	Median	All	0.165	0.707	.046	3	view →
LUAD	DFS	Median	All	0.308	0.678	.014	3	view →
SKCM	DFS	Median	All	1.000	0.614	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

STK17B–ESCA (OS)

Open the ESCA breakdown →